More News

New approach to rare disease drug development yields first research results

Jim Cornall -
A team of scientists and business professionals at Queen Mary University of London have made a significant step towards...

PFAS in medicines can often be replaced with alternatives

Jim Cornall -
Certain medicines contain per- and polyfluorinated alkyl compounds, known as PFAS, which are causing increasing environmental harm due to...

Polyomaviruses: new approaches to prevention and treatment

Jim Cornall -
In people with severely compromised immune systems, the JC polyomavirus can trigger a currently untreatable, usually fatal brain disease. Now,...

ten23 health obtains Swissmedic licences for Basel and Visp facilities

Jim Cornall -
ten23 health, a global contract development and manufacturing organisation (CDMO) focused on sterile and biologic drug products, today announced...

SK bioscience launches initiative to reduce uncertainty in vaccine-development decisions

Jim Cornall -
SK bioscience will lead the Research Optimization & Trial Outcome Recommender (ROTOR) project, an AI-powered evidence synthesis and clinical...

Human embryo gene-correction research approved

Jim Cornall -
Origin Genomics has secured Institutional Review Board (IRB) approval for its human embryo gene-correction research protocol and has launched...

New immunotherapy strategy targets aggressive brain tumours and their fuel

Jim Cornall -
Researchers at McMaster University in Canada have developed a new cancer immunotherapy strategy that can simultaneously attack deadly brain...

New tool gives scientists clearer view of DNA regulation

Jim Cornall -
Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at NUS have developed a new method that allows...

Base to Base biotech podcast 66: The future of clinical trials and breakthroughs in molecular testing

Jim Cornall -
This week, we have a conversation with Jeff Fischer, president of Longhorn Vaccines & Diagnostics, and with Hannah Amies,...

Fast Track Designation for epidermolysis bullosa simplex treatment

Jim Cornall -
BioMendics, LLC, a clinical-stage biotechnology company developing therapies for rare genetic skin disorders, has announced that the U.S. Food...

Enzyme evolves into ‘control switch’ to reveal new TB weak spot

Jim Cornall -
A protein that acts as a 'control switch,' preventing Mycobacterium tuberculosis from accessing the energy sources it needs to...

Abnormally long mitochondria leak RNA to activate anti-tumour immunity

Jim Cornall -
Mitochondria are constantly dividing and fusing within our cells, reshaping themselves to keep up with the cell’s changing needs....

Roche launches new sequencing platform

Jim Cornall -
Roche has launched AXELIOS 1 based on SBX technology, with a combination of accuracy, speed, flexibility, scalability and cost...

New drug for chronic heart failure tested in early study

Jim Cornall -
An early clinical study shows that a new oral drug is safe and well-tolerated in patients with chronic heart...

First clinical evidence of increased lean muscle volume in FSHD patients after EPI-321 treatment

Jim Cornall -
Epicrispr Biotechnologies has announced new interim data from its ongoing open-label phase 1/2 first-in-human study of EPI-321 in facioscapulohumeral...

Mechanism for weakening a bacterium responsible for food poisoning

Jim Cornall -
Scientists from the Department of Microbiology of the University of Malaga in Spain, also members of the Institute of...

New research could lead to vaccine for severe diarrhoea

Jim Cornall -
Research led by the University of Bergen (UiB) in Norway and NORCE may help pave the way for a...

BioArctic and Lilly sign research agreement

Jim Cornall -
BioArctic AB (publ) has entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential...

Biogen boosts immunology pipeline through $1bn RayThera acquisition

Jim Cornall -
Biogen Inc. and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule therapies in immunology,...

Brain tau spreads differently in early- and late-onset Alzheimer’s disease

Jim Cornall -
The amount and distribution of the tau protein in the brain differs between early and late-onset Alzheimer's disease. This...

Base to Base biotech podcast 65: Giving medicine a genetic camouflage

Jim Cornall -
This week, we have a conversation with Houdini Bio CEO and co-founder Jonathan Cohen-Gold. Base to Base biotech podcast 65:...